Metabolomics Approach in Allergic and Rheumatic Diseases
详细信息 查看全文
- 作者：Rossana Scrivo (1)
Luca Casadei (2)
Mariacristina Valerio (2)
Roberta Priori (1)
Guido Valesini (1)
Cesare Manetti (2) - 关键词：Metabolomics ; Metabolite ; Asthma ; Atopic dermatitis ; Rheumatoid arthritis ; Systemic lupus erythematosus ; Allergic diseases ; Rheumatic diseases ; Biomarkers ; Mass spectrometry ; High ; resolution proton nuclear magnetic resonance
- 刊名：Current Allergy and Asthma Reports
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：14
- 期：6
- 全文大小：322 KB
- 参考文献：1. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012;29:613鈥?4. CrossRef
2. Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G, et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev. 2013;12:1022鈥?0. CrossRef
3. Goodacre R, Broadhurst D, Smilde AK, Kristal BS, Baker JD, Beger R, et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics. 2007;3:231鈥?1. CrossRef
4. Fiehn O. Metabolomics鈥攖he link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155鈥?1. CrossRef
5. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:153鈥?2. CrossRef
6. Griffin JL. Metabolic profiles to define the genome: can we hear the phenotypes? Philos Trans R Soc Lond B Biol Sci. 2004;359:857鈥?1. CrossRef
7. Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go the functional genomics ball? Philos Trans R Soc Lond B Biol Sci. 2006;361:147鈥?1. CrossRef
8. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51鈥?8. CrossRef
9. Shushan B. A review of clinical diagnostic applications of liquid chromatographytandem mass spectrometry. Mass Spectrom Rev. 2010;29:930鈥?4. CrossRef
10. Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst. 2002;127:1549鈥?7. CrossRef
11. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469鈥?9. CrossRef
12. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491:384鈥?2. CrossRef
13. Masoli M, Fabian D, Holt S, Beasley R, Program G. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469鈥?8. CrossRef
14. Bisgaard H, Szefler S. Prevalence of asthma鈥恖ike symptoms in young children. Pediatr Pulmonol. 2007;42:723鈥?. CrossRef
15. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715鈥?1. CrossRef
16. Djukanovi膰 R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669鈥?4. CrossRef
17. Carraro S, Rezzi S, Reniero F, Heberger K, Giordano G, Zanconato S, et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med. 2007;175:986鈥?0. CrossRef
18. Saude EJ, Obiefuna IP, Somorjai RL, Ajamian F, Skappak C, Ahmad T, et al. Metabolomic biomarkers in a model of asthma exacerbation urine nuclear magnetic resonance. Am J Respir Crit Care Med. 2009;179:25鈥?4. CrossRef
19. Saude EJ, Skappak CD, Regush S, Cook K, Ben-Zvi A, Becker A, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol. 2011;127:757鈥?4. CrossRef
20. Mattarucchi E, Baraldi E, Guillou C. Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr. 2011;26:89鈥?4. CrossRef
21. Brightling CE, Green RH, Pavord ID. Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med. 2005;4:309鈥?6. CrossRef
22. Horvath I, Barnes P, Hunt J. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523鈥?8. CrossRef
23. Carraro S, Giordano G, Reniero F, Carpi D, Stocchero M, Sterk PJ, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy. 2013;68:110鈥?. / Provided evidence that metabolomic profiling may allow a full discrimination of asthma phenotype, suggesting that this approach may be used to develop new targeted therapies. CrossRef
24. Ibrahim B, Marsden P, Smith JA, Custovic A, Nilsson M, Fowler SJ. Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma. Allergy. 2013;68:1050鈥?. CrossRef
25. Canning BJ. Modeling asthma and COPD in animals: a pointless exercise? Curr Opin Pharmacol. 2003;3:244鈥?0. CrossRef
26. Evans CM, Fryer AD, Jacoby DB, Gleich GJ, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest. 1997;100:2254鈥?2. CrossRef
27. Gibbs NK, Tye J, Norval M. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem Photobiol Sci. 2008;7:655鈥?7. CrossRef
28. Ho WE, Xu YJ, Xu F, Cheng C, Peh HY, Tannenbaum SR, et al. Metabolomics reveals altered metabolic pathways in experimental asthma. Am J Respir Cell Mol Biol. 2013;48:204鈥?1. CrossRef
29. Jung J, Kim SH, Lee HS, Choi GS, Jung YS, Ryu DH, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy. 2013;43:425鈥?3. / Provided evidence that 1H NMR metabolomics may distinguish between adult patients with asthma and healthy subjects; the levels of serum metabolites from patients correlated with disease severity. CrossRef
30. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483鈥?4. CrossRef
31. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67:1475鈥?2. CrossRef
32. Hanifin JM. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. J Invest Dermatol. 2009;129:320鈥?. CrossRef
33. Assfalg M, Bortoletti E, D'Onofrio M, Pigozzi R, Molinari H, Boner AL, et al. An exploratory (1) H-nuclear magnetic resonance metabolomics study reveals altered urine spectral profiles in infants with atopic dermatitis. Br J Dermatol. 2012;166:1123鈥?. CrossRef
34. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094鈥?08. CrossRef
35. Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol. 2012;39:212鈥?. CrossRef
36. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:431鈥?. CrossRef
37. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2013 Apr 9 [Epub ahead of print].
38. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011;70:1713鈥?. CrossRef
39. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res. 2007;9:3456鈥?4. CrossRef
40. Rantap盲盲-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991;50:366鈥?. CrossRef
41. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta. 2012;1821:1415鈥?4.
42. van Wietmarshchen HA, Dai W, van der Kooij AJ, Reijmers TH, Schroen Y, Wang M, et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS One. 2012;7:e44331. CrossRef
43. Jiang M, Xiao C, Chen G, Lu C, Zha Q, Yan X, et al. Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis. Front Med. 2011;5:219鈥?8. CrossRef
44. Gu Y, Lu C, Zha Q, Kong H, Lu X, Lu A, et al. Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Mol BioSyst. 2012;8:1535鈥?3. CrossRef
45. Lauridsen MB, Bliddal H, Christensen R, Danneskiold-Sams酶e B, Bennett R, Keun H, et al. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res. 2010;9:4545鈥?3. CrossRef
46. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65:2015鈥?3. CrossRef
47. Wang Z, Chen Z, Yang S, Wang Y, Yu L, Zhang B, et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. Exp Ther Med. 2012;4:165鈥?1. / Provided evidence that metabolic changes may predict the response to methotrexate in patients with rheumatoid arthritis.
48. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor 伪 therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448鈥?6. / Provided evidence that metabolic changes may predict the response to biological agents in patients with rheumatoid arthritis. CrossRef
49. Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R19. CrossRef
50. Meshitsuka S, Yamazaki E, Inoue M, Hagino H, Teshima R, Yamamoto K. Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Clin Chim Acta. 1999;281:163鈥?. CrossRef
51. H眉gle T, Kovacs H, Heijnen IA, Daikeler T, Baisch U, Hicks JM, et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol. 2012;30:240鈥?.
52. Wallace D, Hahn BH. Dubois鈥?lupus erythematosus and related syndromes. 8th ed. Philadelphia: Sanders Elsevier; 2013.
53. Ouyang X, Dai Y, Wen JL, Wang LX. 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. Lupus. 2011;20:1411鈥?0. CrossRef
54. Romick-Rosendale LE, Brunner HI, Bennett MR, Mina R, Nelson S, Petri M, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther. 2011;13:R199. CrossRef
55. Quaggin SE, Kreidberg JA. Development of the renal glomerulus: good neighbors and good fences. Development. 2008;135:609鈥?0. CrossRef
56. Komatsu N, Kodama K, Yamanouchi N, Okada S, Noda S, Nawata Y, et al. Metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol. 1999;42:41鈥?. CrossRef
57. Alexander JJ, Zwingmann C, Quigg R. MRL/lpr mice have alterations in brain metabolism as shown with [1H-13C] NMR spectroscopy. Neurochem Int. 2005;47:143鈥?1. CrossRef
58. Laptook AR, Peterson J, Michael PA. Effects of lactic acid infusions and pH on cerebral blood flow and metabolism. J Cereb Blood Flow Metabol. 1988;8:193鈥?00. CrossRef
59. Wu T, Xie C, Han J, Ye Y, Weiel J, Li Q, et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS One. 2012;7:e37210. CrossRef
60. Ding X, Hu J, Wen C, Ding Z, Yao L, Fan Y. Rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry-based metabolomics approach to study the effects of Jieduquyuziyin prescription on systemic lupus erythematosus. PLoS One. 2014;9:e88223. CrossRef - 作者单位：Rossana Scrivo (1)
Luca Casadei (2)
Mariacristina Valerio (2)
Roberta Priori (1)
Guido Valesini (1)
Cesare Manetti (2)
1. Dipartimento di Medicina Interna e Specialit脿 Mediche, Reumatologia, Sapienza Universit脿 di Roma, Viale del Policlinico 155, 00161, Rome, Italy
2. Dipartimento di Chimica, Sapienza Universit脿 di Roma, Piazzale Aldo Moro 5, 00185, Rome, Italy - ISSN：1534-6315
文摘
Metabolomics is the analysis of the concentration profiles of low molecular weight compounds present in biological fluids. Metabolites are nonpeptide molecules representing the end products of cellular activity. Therefore, changes in metabolite concentrations reveal the range of biochemical effects induced by a disease or its therapeutic intervention. Metabolomics has recently become feasible with the accessibility of new technologies, including mass spectrometry and high-resolution proton nuclear magnetic resonance, and has already been applied to several disorders. Indeed, it has the advantage of being a nontargeted approach for identifying potential biomarkers, which means that it does not require a preliminary knowledge of the substances to be studied. In this review, we summarize the main studies in which metabolomic approach was used in some allergic (asthma, atopic dermatitis) and rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus) to explore the feasibility of this technique as a novel diagnostic tool in these complex disorders.